A Phase I Study of CC-92480 and Dexamethasone for Patients with Recurrent or Persistent Multiple Myeloma

Full Title

A Phase 1 Multicenter, Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma


The purpose of this study is to assess the safety of treatment with the investigational drug CC-92480 in combination with dexamethasone for patients with multiple myeloma that has come back or continued to grow despite standard therapy. CC-92480 is a type of drug called a “cereblon-modifying (CM) agent.”

Other CM agents used to treat multiple myeloma include thalidomide, lenalidomide, and pomalidomide. CC-92480 is a new CM agent that is thought to be more effective for targeting and destroying proteins that help to produce myeloma cells. The effect of CC-92480 may be increased when it is used in combination with dexamethasone, a standard part of myeloma treatment. Both CC-92480 and dexamethasone are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that continued to grow or came back despite prior treatment that included a proteasome inhibitor (bortezomib or carfilzomib) and a CM agent.
  • At least 4 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ola Landgren at 212-639-5126.





Disease Status

Relapsed or Refractory